Kestrel Therapeutics Inc. filed a Form D with the Securities and Exchange Commission on 2025-08-12.
Kestrel Therapeutics Inc. filed a Form D notice of an exempt securities offering with the SEC on August 12, 2025. The filing reports $5M sold. Its industry group is Biotechnology. It names Frank Haluska (Executive Officer, Director), Denis Patrick (Director), Omar Khalil (Director) (SEC Form D, August 12, 2025).
Is this your company?
Sell to companies like Kestrel Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-08-12 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Kestrel Therapeutics Inc.
Free to see. No signup.
More on the people and the money behind Kestrel Therapeutics Inc., from the filings we hold.
Biotechnology raises by companies based in Massachusetts, filed in August 2025, largest first.
Get an email when Kestrel Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Kestrel Therapeutics Inc. raises, hires or launches. No email unless you switch it on.
Watch Kestrel Therapeutics Inc. →Get the full cited report on Kestrel Therapeutics Inc.
What the filing shows about Kestrel Therapeutics Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Kestrel Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Kestrel Therapeutics Inc.'s address as Attn: Pagliuca Harvard Life Lab, 127 Western Ave., Boston, MA 02134.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Kestrel Therapeutics Inc. See pricing
Kestrel Therapeutics Inc. is a registered filer with the SEC (CIK 1853373) and has filed since 2025-02-21. 2 filings are on record, the latest on 2025-08-12.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Kestrel Therapeutics Inc.'s Form D of 2025-08-12 names Frank Haluska, Denis Patrick, Omar Khalil and 3 more as its officers, directors or promoters.
Its new offerings report $13M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 769 filings in Biotechnology, totalled by week.
Checked away from the filing. What is below does not come from the record on sec.gov.
Kestrel Therapeutics discovers and develops new molecules to treat intractable cancers using targeted therapy.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Frank Haluska is named as Executive Officer and Director on the Form D that Kestrel Therapeutics Inc. filed with the SEC on 12 August 2025, one of 6 people that filing names.
Denis Patrick is named as Director on the Form D that Kestrel Therapeutics Inc. filed with the SEC on 12 August 2025, one of 6 people that filing names.
Omar Khalil is named as Director on the Form D that Kestrel Therapeutics Inc. filed with the SEC on 12 August 2025, one of 6 people that filing names.
Andrew Phillips is named as Director on the Form D that Kestrel Therapeutics Inc. filed with the SEC on 12 August 2025, one of 6 people that filing names.
Nicholas Saccomano is named as Director on the Form D that Kestrel Therapeutics Inc. filed with the SEC on 12 August 2025, one of 6 people that filing names.
Barbara Sosnowski is named as Director on the Form D that Kestrel Therapeutics Inc. filed with the SEC on 12 August 2025, one of 6 people that filing names.
6 people named on the filing — 1 holding an executive role and 5 as directors only.
Named as of the 2025-08-12 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Kestrel Therapeutics Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Kestrel Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kestrel Therapeutics Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Kestrel Therapeutics Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Kestrel Therapeutics Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-11-01 (kestreltherapeutics.com).
Each opens in a new tab, filled in for Kestrel Therapeutics Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Boston
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/kestrel-therapeutics-inc-form-d-25000001